407 related articles for article (PubMed ID: 25077370)
61. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
62. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
63. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.
Wong H; Lau S; Yau T; Cheung P; Epstein RJ
Br J Cancer; 2010 Apr; 102(9):1391-6. PubMed ID: 20424617
[TBL] [Abstract][Full Text] [Related]
64. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.
Qi L; Bart J; Tan LP; Platteel I; Sluis Tv; Huitema S; Harms G; Fu L; Hollema H; Berg Av
BMC Cancer; 2009 May; 9():163. PubMed ID: 19473551
[TBL] [Abstract][Full Text] [Related]
65. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
66. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
67. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
68. Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer.
Strang LR; Sun J; Sun W; Boulware D; Kiluk JV; Lee MC; Khazai L; Laronga C
J Surg Res; 2020 Oct; 254():378-383. PubMed ID: 32535256
[TBL] [Abstract][Full Text] [Related]
69. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
Ottesen GL; Christensen IJ; Larsen JK; Larsen J; Baldetorp B; Linden T; Hansen B; Andersen J
Breast Cancer Res Treat; 2000 Apr; 60(3):219-26. PubMed ID: 10930109
[TBL] [Abstract][Full Text] [Related]
70. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
71. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
[TBL] [Abstract][Full Text] [Related]
72. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast.
Rudas M; Neumayer R; Gnant MF; Mittelböck M; Jakesz R; Reiner A
Eur J Cancer; 1997 Jan; 33(1):39-44. PubMed ID: 9071897
[TBL] [Abstract][Full Text] [Related]
73. Prediction of heterogeneity in breast cancer immunophenotype at ductal carcinoma
Rohilla M; Bal A; Singh G; Joshi K
J Cancer Res Ther; 2016; 12(4):1249-1256. PubMed ID: 28169235
[TBL] [Abstract][Full Text] [Related]
74. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
75. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
76. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
77. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
78. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
79. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
80. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
Padmore RF; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky AS
Cancer; 2000 Mar; 88(6):1403-9. PubMed ID: 10717623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
